Dendreon sells royalty interest in Merck's hep C drug Victrelis for $125M
This article was originally published in Scrip
Executive Summary
Dendreon is boosting its cash reserves by selling its royalty interest in the Merck & Co hepatitis C drug Victrelis (boceprevir) ) to Canada’s national pension fund CPPIB Credit Investments for $125 million. The transaction is expected to close this month.